Ipsogen Launches A New Test To Determine Tumor HER2 Status And Guide Herceptin(R) Prescription In Breast Cancer

IPSOGEN SA (Marseille, France and New Haven, CT, USA), a cancer profiler that markets molecular diagnostic assays for leukemia and breast cancer announced the European launch of MapQuant Dx(TM) HER2 test. Developped on the MapQuant Dx(TM) microarray diagnostic platform, MapQuant Dx(TM) HER2 accurately measures a set of HER2-amplified genes that correlate with HER2 protein expression.

More: continued here

Filed under: Breast Cancer on November 25th, 2008